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‘‘For  in  every  adult  there  dwells  the  child  that  was,  and
in  every  child  there  lies  the  adult  that  will  be.’’
--  John  Connolly,  The  Book  of  Lost  Things
Introduction and overview
The  11th  World  Kidney  Day  will  be  celebrated  on  March  10,
2016,  around  the  globe.  This  annual  event,  sponsored  jointly
by  the  International  Society  of  Nephrology  (ISN)  and  the
International  Federation  of  Kidney  Foundations  (IFKF),  has
become  a  highly  successful  effort  to  inform  the  general  pub-
lic  and  policymakers  about  the  importance  and  ramiﬁcations
of  kidney  disease.  In  2016,  World  Kidney  Day  will  be  dedi-
cated  to  kidney  disease  in  childhood  and  the  antecedents  of
adult  kidney  disease,  which  can  begin  in  earliest  childhood.
Children  who  endure  acute  kidney  injury  (AKI)  from  a
wide  variety  of  conditions  may  have  long-term  sequelae
that  can  lead  to  chronic  kidney  disease  (CKD)  many  years
later.1--4 Further,  CKD  in  childhood,  much  of  it  congenital,
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license (https://creativecommons.org/licenses/by/4.0/).nd  complications  from  the  many  non-renal  diseases  that
an  affect  the  kidneys  secondarily,  not  only  lead  to  sub-
tantial  morbidity  and  mortality  during  childhood  but  also
esult  in  medical  issues  beyond  childhood.  Indeed,  childhood
eaths  from  a  long  list  of  communicable  diseases  are  inextri-
ably  linked  to  kidney  involvement.  For  example,  children
ho  succumb  to  cholera  and  other  diarrheal  infections  often
ie,  not  from  the  infection,  but  because  of  AKI  induced  by
olume  depletion  and  shock.  In  addition,  a  substantial  body
f  data  indicates  that  hypertension,  proteinuria  and  CKD  in
dulthood  have  childhood  antecedents  --  from  as  early  as
n  utero  and  perinatal  life  (see  Table  1  for  deﬁnitions  of
hildhood).  World  Kidney  Day  2016  aims  to  heighten  general
wareness  that  much  adult  renal  disease  is  actually  initiated
n  childhood.  Understanding  high  risk  diagnoses  and  events
hat  occur  in  childhood  have  the  potential  to  identify  and
ntervene  preemptively  in  those  people  at  higher  risk  for
KD  during  their  lifetimes.
Worldwide  epidemiologic  data  on  the  spectrum  of  both
KD  and  AKI  in  children  are  currently  limited,  though
ncreasing  in  scope.  The  prevalence  of  CKD  in  childhood  is
are  --  and  has  been  variously  reported  at  15--74.7  per  mil-
ion  children.3 Such  variation  is  likely  because  data  on  CKD
re  inﬂuenced  by  regional  and  cultural  factors,  as  well  as  by
he  methodology  used  to  generate  them.  The  World  Health
rganization  (WHO)  has  recently  added  kidney  and  urologic
isease  to  mortality  information  tracked  worldwide,  and
evier Editora Ltda. This is an open access article under the CC BY
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Table  1  Deﬁnitions  of  stages  of  early  life.
Perinatal  period  22  completed  weeks  of  gestation  to
Day  7  of  postnatal  life
Neonatal  period  Birth  to  Day  28  of  postnatal  life
Infancy  Birth  to  1  year  of  age
Childhood  1  year  of  age  to  10  years  of  age
Adolescence  10  years  of  age  to  19  years  of  age
Notes: The data in this table are as deﬁned by the World Health
Organization.
There is variation worldwide in how these stages of early life
are deﬁned. Some would deﬁne ‘‘young people’’ as those age
24 or less. In the United States, childhood is as a whole deﬁned
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Table  2  Etiology  of  chronic  kidney  disease  in  children.2
CKD  ESRD
Etiology  Percentage
(range)
Etiology  Percentage
(range)
CAKUT  48--59%  CAKUT  34--43%
GN 5--14% GN  15--29%
HN 10--19% HN  12--22%
HUS 2--6% HUS  2--6%
Cystic  5--9%  Cystic  6--12%
Ischemic  2--4%  Ischemic  2%
CKD, chronic kidney disease; ESRD, childhood onset end-stage
renal disease; CAKUT, congenital anomalies of the kidney and
urinary tract; GN, glomerulonephritis; HN, hypertension; HUS,
hemolytic uremic syndrome. Rare causes include congenital NS,
metabolic diseases, cystinosis. Miscellaneous causes depend on
how such entities are classiﬁed.
Chronic Kidney Disease data are from North American Pediatric
Renal Trials and Collaborative Studies, the Italian Registry and
the Belgian Registry. Childhood onset end-stage renal disease
data are from ANZDATA, ESPN/ERA-EDTA, UK Renal Registry and
the Japanese Registry.
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hould  be  a  valuable  source  of  such  data  over  time  --  yet
HO  does  not  post  the  information  by  age  group.5 Databases
uch  as  the  North  American  Pediatric  Renal  Trials  and  Col-
aborative  Studies  (NAPRTCS)6 the  U.S.  Renal  Data  System
USRDS)7 and  the  EDTA  registry8 include  data  on  pediatric
nd-stage  renal  disease,  and  some  on  CKD.  Projects  such  as
he  ItalKid9 and  Chronic  Kidney  Disease  in  Children  (CKiD)10
tudies,  the  Global  Burden  of  Disease  Study  2013,  as  well  as
egistries  that  now  exist  in  many  countries  provide  impor-
ant  information,  and  more  is  required.11
AKI  may  lead  to  CKD,  according  to  selected  adult  popula-
ion  studies.12 The  incidence  of  AKI  among  children  admitted
o  an  intensive  care  unit  varies  widely  --  from  8%  to  89%.1 The
utcome  depends  on  the  available  resources.  The  results
rom  projects  such  as  the  AWARE  study,  a  ﬁve-nation  study  of
KI  in  children  are  awaited.13 Single  center  studies,  as  well
s  meta-analyses  indicate  that  both  AKI  and  CKD  in  children
ccount  for  a  minority  of  CKD  worldwide.2,3 However,  it  is
ncreasingly  evident  that  kidney  disease  in  adulthood  often
prings  from  a  childhood  legacy.
pectrum of pediatric kidney diseases
he  conditions  that  account  for  CKD  in  childhood,  with  a
redominance  of  congenital  and  hereditary  disorders,  dif-
er  substantially  from  those  in  adults.  To  date,  mutations
n  more  than  150  genes  have  been  found  to  alter  kidney
evelopment  or  speciﬁc  glomerular  or  tubular  functions.14
ost  of  these  genetic  disorders  present  during  childhood,
nd  many  lead  to  progressive  CKD.  Congenital  anomalies
f  the  kidney  and  urinary  tract  (CAKUT)  account  for  the
argest  category  of  CKD  in  children  (see  Table  2)  and  include
enal  hypoplasia/dysplasia  and  obstructive  uropathy.  Impor-
ant  subgroups  among  the  renal  dysplasias  are  the  cystic
idney  diseases,  which  originate  from  genetic  defects  of
he  tubuloepithelial  cells’  primary  cilia.  Many  pediatric
lomerulopathies  are  caused  by  genetic  or  acquired  defects
f  the  podocytes,  the  unique  cell  type  lining  the  glomerular
apillaries.  Less  common  but  important  causes  of  childhood
KD  are  inherited  metabolic  disorders  such  as  hyperoxaluria
nd  cystinosis,  and  atypical  hemolytic  uremic  syndrome,  a
hrombotic  microangiopathy  related  to  genetic  abnormali-
ies  of  complement,  coagulation  or  metabolic  pathways.
In  various  classiﬁcations  it  is  not  clear  how  to  categorize
hildren  who  have  suffered  AKI  and  apparently  recovered,
I
m
a
mr  how  and  whether  to  include  those  children  who  have
ad  perinatal  challenges,  likely  resulting  in  a relatively  low
ephron  number.
Among  children  with  childhood-onset  end-stage  renal
isease  (ESRD)  glomerulopathies  are  slightly  more  and  con-
enital  anomalies  less  common  (Table  2),  due  to  the  typically
ore  rapid  nephron  loss  in  glomerular  disease.  However,
ecent  evidence  suggests  that  many  patients  with  milder
orms  of  CAKUT  may  progress  to  ESRD  during  adulthood,
eaking  in  the  fourth  decade  of  life.15
There  are  national  and  regional  differences  in  the  types
nd  course  of  both  AKI  and  CKD  during  childhood  and
eyond.  Death  from  kidney  disease  is  higher  in  develop-
ng  nations,  and  national  and  regional  disparities  in  care
nd  outcome  must  be  addressed.  Further,  access  to  care
s  variable,  depending  on  the  region,  the  country  and  its
nfrastructure.  By  focusing  on  kidney  disease  in  childhood,
ost-effective  solutions  may  be  reached,  as  treating  disease
arly  and  preemptively  may  prevent  later,  more  advanced
KD.  Expectations  depend  on  the  availability  of  care  and
anagement.  Treating  children,  even  from  infancy,  who
ave  AKI  and  CKD  that  requires  renal  replacement  therapy
an  be  effective  in  mitigating  the  burden  of  kidney  disease
n  adulthood.  Doing  so  requires  resources  that  focus  on  the
ost  expeditious  and  cost-effective  ways  to  deliver  acute
RT  in  childhood.
ongenital kidney disease and developmental
rigins of health and disease, renal
ndowment and implicationsn  regions  where  antenatal  fetal  ultrasounds  are  routine,
any  children  with  urologic  abnormalities  are  identiﬁed
ntenatally,  which  permits  early  intervention.  However,  in
uch  of  the  world,  children  with  structural  abnormalities
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aFocus  on  childhood  
are  not  identiﬁed  until  much  later,  when  symptoms  develop.
While  generalized  screening  for  proteinuria,  hematuria  and
urinary  tract  infections  are  carried  out  in  some  countries
and  regions,  there  is  a  lack  of  consensus  as  to  its  effec-
tiveness.  However,  there  is  general  agreement  that  children
with  antenatal  ultrasound  studies  that  indicate  possible  gen-
itourinary  anomalies,  children  with  a  family  history  of  kidney
disease,  and  children  with  signs  such  as  failure  to  thrive
or  a  history  of  urinary  tract  infection,  voiding  dysfunc-
tion  or  an  abnormal  appearing  urine  should  be  examined.
Initial  screening  would  include  a  focused  physical  exami-
nation  and  a  urine  dipstick,  formal  urinalysis  and  a  basic
chemistry  panel,  followed  by  a  more  focused  evaluation  if
indicated.
Depending  on  the  diagnosis,  deﬁnitive  therapy  may  be
indicated.  However,  the  evidence  that  therapy  will  slow  pro-
gression  of  CKD  in  childhood  remains  limited.  Angiotensin
converting  enzyme  inhibitors,  angiotensin  receptor  block-
ers,  antioxidants  and,  possibly,  dietary  changes  may  be
indicated,  depending  on  the  diagnosis.  However,  dietary
changes  need  to  permit  adequate  growth  and  develop-
ment.  The  ESCAPE  trial  provided  evidence  that  strict  blood
pressure  control  retards  progression  of  CKD  in  children  irre-
spective  of  the  type  of  underlying  kidney  disease.16
Some  very  young  children  may  require  renal  replacement
therapy  in  early  infancy.  Recent  data  pooled  from  registries
worldwide  indicate  good  survival,  even  when  dialysis  is
required  from  neonatal  age.2,17 Kidney  transplantation,  the
preferred  renal  replacement  therapy  in  children,  is  gener-
ally  suitable  after  12  months  of  age,  with  excellent  patient
and  allograft  survival,  growth  and  development  (Fig.  1).
Evidence  is  accumulating  that  childhood-onset  CKD  leads
to  accelerated  cardiovascular  morbidity  and  shortened  life
expectancy.  Ongoing  large  prospective  studies  such  as  the
(Cardiovascular  Comorbidity  in  Children  with  CKD  (4C)  Study
are  expected  to  inform  about  the  causes  and  consequences
of  early  cardiovascular  disease  in  children  with  CKD.18
In  addition  to  those  children  with  congenital  kidney  dis-
ease,  it  is  now  known  that  perinatal  events  may  affect  future
health  in  the  absence  of  evident  kidney  disease  in  early
life.19 Premature  infants  appear  to  be  particularly  at  risk
for  kidney  disease  long  after  they  are  born,  based  both  on
observational  cohort  studies,  as  well  as  on  case  reports.
Increasingly  premature  infants  survive,  including  many  born
well  before  nephrogenesis  is  complete.20 The  limited  data
available  indicate  that  in  the  process  of  neonatal  ICU  care,
such  babies  receive  many  nephrotoxins,  and  that  those  dying
prior  to  discharge  from  the  nursery  have  fewer  and  larger
glomeruli.21 Additionally,  those  surviving  have  evidence  of
renal  impairment  that  may  be  subtle.22 Even  more  concern-
ing,  abundant  epidemiologic  data  indicate  that  persons  born
at  term  but  with  relatively  low  birth  weights  may  be  at  high
risk  for  hypertension,  albuminuria  and  CKD  in  later  life.23
When  direct  measurements  are  pursued,  such  persons,  as
adults,  may  have  fewer  nephrons,  thus  a  low  cardiorenal
endowment.
In  focusing  on  children  for  World  Kidney  Day,  we  would
note  that  it  is  key  to  follow  kidney  function  and  blood
pressure  throughout  life  in  those  persons  born  early  or
small-for-dates.  By  doing  so,  and  avoiding  nephrotoxic  med-
ications  throughout  life,  it  may  be  possible  to  avert  CKD  in
many  people.
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esources and therapeutics for children --
ifferences from therapeutics in adults
isparities  exist  in  the  availability  of  resources  to  treat  AKI
n  children  and  young  people;  consequently,  too  many  chil-
ren  and  young  adults  in  developing  nations  succumb  if
KI  occurs.  To  address  the  problem  the  ISN  has  initiated
he  Saving  Young  Lives  Project,  which  aims  both  to  prevent
KI  with  prompt  treatment  of  infection  and/or  delivery  of
ppropriate  ﬂuid  and  electrolyte  therapy,  and  to  treat  AKI
hen  it  occurs.  This  ongoing  project  in  SubSaharan  Africa
nd  South  East  Asia,  in  which  four  kidney  foundations  par-
icipate  equally  [IPNA  (International  Pediatric  Nephrology
ssociation),  ISN  (International  Society  of  Nephrology),  ISPD
International  Society  for  Peritoneal  Dialysis),  SKCF  (Sustain-
ble  Kidney  Care  Foundation)],  focuses  on  establishing  and
aintaining  centers  for  the  care  of  AKI,  including  the  provi-
ion  of  acute  peritoneal  dialysis.  It  links  with  the  ISN’s  0  by
5  project,  which  calls  on  members  to  ensure  by  2025  that
obody  dies  from  preventable  and  acute  kidney  injury.
In  view  of  the  preponderance  of  congenital  and  heredi-
ary  disorders,  therapeutic  resources  for  children  with  CKD
ave  historically  been  limited  to  a  few  immunological  condi-
ions.  Very  recently,  progress  in  drug  development  in  concert
ith  advances  in  genetic  knowledge  and  diagnostic  capabil-
ties  has  begun  to  overcome  the  long-standing  ‘therapeutic
ihilism’  in  pediatric  kidney  disease.  Atypical  HUS,  long  con-
idered  ominous,  with  a  high  likelihood  of  progression  to
SRD  and  post-transplantation  recurrence,  has  turned  into
 treatable  condition  --  with  the  advent  of  a monoclonal
ntibody  that  speciﬁcally  blocks  C5  activation.24 Another
xample  is  the  use  of  vasopressin  receptor  antagonists  to
etard  cyst  growth  and  preserve  kidney  function  in  polycys-
ic  kidney  disease.25 First  proven  efﬁcacious  in  adults  with
utosomal  dominant  polycystic  kidney  disease,  therapy  with
aptans  holds  promise  also  for  the  recessive  form  of  the  dis-
ase,  which  presents  and  often  progresses  to  ESRD  during
hildhood.
However,  patient  beneﬁt  from  pharmacological  research
reakthroughs  is  jeopardized  on  a  global  scale  by  the  enor-
ous  cost  of  some  of  the  new  therapeutic  agents.  The  quest
or  affordable  innovative  therapies  for  rare  diseases  will  be
 key  issue  in  pediatric  nephrology  in  the  years  to  come.
The  identiﬁcation  of  children  likely  to  beneﬁt  from  novel
herapeutic  approaches  will  be  greatly  facilitated  by  the
evelopment  of  clinical  registries  that  inform  about  the
atural  disease  course,  including  genotype--phenotype  cor-
elations.  Apart  from  disease-speciﬁc  databases,  there  is
lso  a  need  for  treatment-speciﬁc  registries.  These  are  par-
icularly  relevant  in  areas  where  clinical  trials  are  difﬁcult  to
erform  due  to  small  patient  numbers  and  lacking  industry
nterest,  as  well  as  for  therapies  in  need  of  global  devel-
pment  or  improvement.  For  instance,  there  is  currently
 large  international  gradient  in  the  penetration  and  per-
ormance  of  pediatric  dialysis  and  transplantation.  Whereas
ediatric  patient  and  technique  survival  rates  are  excellent
nd  even  superior  to  those  of  adults  in  many  industrialized
ountries,  it  is  estimated  that  almost  half  of  the  world’s
hildhood  population  is  not  offered  chronic  renal  replace-
ent  therapy  (RRT)  at  all.  Providing  access  to  RRT  for  all
hildren  will  be  a  tremendous  future  challenge.  To  obtain
8  Ingelﬁnger  JR  et  al.
Congenital Kidney Disease
or Inherited Disorders
Acquired Kidney Disease
Contribution of nephron number
Contribution of life challenges
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Nigure  1  The  types  and  risks  of  kidney  disease  change  acros
he life  cycle,  in  concert  with  events  that  provide  direct  insults
eliable  information  on  the  demographics  and  outcomes  of
ediatric  RRT,  the  International  Pediatric  Nephrology  Asso-
iation  (IPNA)  is  about  to  launch  a  global  population-based
egistry.  If  successful,  the  IPNA  RRT  registry  might  become
 role  model  for  global  data  collection.
ransition from pediatric to adult care
ransition  of  care  for  adolescents  with  kidney  disease  into
n  adult  setting  is  critical  both  for  patients  and  their
aregivers.  Non-adherence  is  a  too-frequent  hallmark  of
ransition  from  pediatric  to  adult  care  for  young  patients
ith  chronic  disease  states.26--28 Hence,  considered  steps
ombined  with  systematically  deﬁned  procedures  supported
y  validated  pathways  and  credible  guidelines  must  be  in
lace  to  ensure  successful  outcomes.
In  the  process  of  change  from  pediatric  to  adult  care
‘transition,’’  which  should  occur  gradually,  must  be  dis-
inguished  from  ‘‘transfer,’’  which  is  often  an  abrupt  and
echanistic  change  in  provider  setting.  Introducing  the
oncept  of  transition  should  be  preemptive,  starting  months
o  years  prior  to  the  targeted  time,  as  children  move  into
dolescence  and  adulthood.  The  ultimate  goal  is  to  foster  a
trong  relationship  and  individualized  plan  in  the  new  set-
ing  that  allows  the  patient  to  feel  comfortable  enough  to
eport  non-adherence  and  other  lapses  in  care.
A  transition  plan  must  recognize  that  the  emotional
aturity  of  children  with  kidney  disease  may  differ  widely.
ssessment  of  the  caregiver  and  the  family  structure  as  well
s  cultural,  social,  and  ﬁnancial  factors  at  the  time  of  tran-
ition  are  key,  including  a  realistic  assessment  of  caregiver
urden.4 The  appropriate  timing  and  format  of  transition
ay  vary  widely  among  different  patients  and  in  different
ettings;  therefore,  a  ﬂexible  process  without  a  set  date  and
ven  without  a  delineated  format  may  be  preferred.
k
i
i lifecycle.  The  contribution  of  nephron  number  increases  over
 challenges  to  kidney  health.
Importantly,  transition  may  need  to  be  slowed,  paused
r  even  reversed  temporarily  during  crises  such  as  disease
ares  or  progression,  or  if  family  or  societal  instability
ccurs.  A  recent  joint  consensus  statement  by  the  Interna-
ional  Society  of  Nephrology  (ISN)  and  International  Pediatric
ephrology  Association  (IPNA)  proposed  steps  consistent
ith  the  points  just  outlined,  aiming  to  enhance  the  transi-
ion  of  care  in  kidney  disease  in  clinical  practice.29,30
all for generating further information and
ction
iven  vulnerabilities  of  children  with  kidney  disease  includ-
ng  impact  on  growth  and  development  and  future  life  as  an
dult,  and  given  the  much  greater  proportion  of  children
n  developing  nations  facing  resource  constraints  educat-
ng  everyone  involved  is  imperative  in  order  to  realign
ommunications  and  actions.31,32 These  efforts  should  fos-
er  regional  and  international  collaborations  and  exchange
f  ideas  between  local  kidney  foundations,  professional
ocieties,  other  not-for-proﬁt  organizations,  and  states  and
overnments,  so  as  to  help  empower  all  stakeholders  to
mprove  the  health,  well-being  and  quality  of  life  of  chil-
ren  with  kidney  diseases  and  to  ensure  their  longevity  into
dulthood.
Until  recently,  however,  the  WHO  consensus  statement  on
on-communicable  diseases  (NCD)  included  cardiovascular
isease,  cancer,  diabetes  and  chronic  respiratory  disease,
ut  not  kidney  disease.33,34 Fortunately,  due,  in  part,  to  a
lobal  campaign  led  by  the  ISN,  the  Political  Declaration  on
CDs  from  the  United  Nations  Summit  in  2011  mentioned
idney  disease  under  Item  19.35
Increasing  education  and  awareness  about  renal  diseases
n  general  and  kidney  disease  in  childhood  in  particular
s  consistent  with  the  objectives  of  the  WHO  to  reduce
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mortality  from  NCD  with  a  10  year  target  population
level  initiatives  focusing  on  changes  in  life  style  (including
tobacco  use  reduction,  salt  intake  control,  dietary  energy
control,  and  alcohol  intake  reduction)  and  effective  inter-
ventions  (including  blood  pressure,  cholesterol  and  glycemic
control).
Heightened  efforts  are  needed  to  realign  and  expand
these  multidisciplinary  collaborations  with  more  effective
focus  on  early  detection  and  management  of  kidney  disease
in  children.  Whereas  the  issues  related  to  kidney  disease
may  be  overshadowed  by  other  NCDs  with  apparently  larger
public  health  implications  such  as  diabetes,  cancer,  and
cardiovascular  diseases,  our  efforts  should  also  increase
education  and  awareness  on  such  overlapping  conditions  as
cardiorenal  connections,  the  global  nature  of  the  CKD  and
ESRD  as  major  NCDs,  and  the  role  of  kidney  disease  as  the
multiplier  disease  and  confounder  for  other  NCDs.  White
papers  including  consensus  articles  and  blueprint  reviews
by  world  class  experts  can  serve  to  enhance  these  goals.36
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